Ascendis Pharma A/S (ASND) P/E Ratio History
UndervaluedTrading at 19.0x vs 5Y avg 23.5x · 33th percentile · Below historical baseline · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of November 18, 2026, Ascendis Pharma A/S (ASND) trades at a price-to-earnings ratio of 19.0x, with a stock price of $271.19 and trailing twelve-month earnings per share of $12.96.
The current P/E is 19% below its 5-year average of 23.5x. Over the past five years, ASND's P/E has ranged from a low of 16.9x to a high of 30.3x, placing the current valuation at the 33th percentile of its historical range.
Compared to the Healthcare sector median P/E of 25.0x, ASND trades at a 24% discount to its sector peers. The sector includes 249 companies with P/E ratios ranging from 0.0x to 184.2x.
Relative to the broader market, ASND trades roughly in line with the S&P 500 median P/E of 21.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ASND DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ASND Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ASND P/E vs Peers
Rare Disease Commercial Leaders peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $24B | 60.0 | -Best | +4173%Best | |
| $15B | 75.6 | -Best | -168% | |
| $3B | 8.9Lowest | -Best | +68% | |
| $9B | 40.9 | -Best | +128% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ASND Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $227.83 | $13.52 | 16.9x | -28% |
| FY2026 Q2 | - | $266.72 | $11.45 | 23.3x | -1% |
| FY2026 Q1 | - | $228.73 | $7.55 | 30.3x | +29% |
Average P/E for displayed period: 23.5x
ASND Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ASND — Frequently Asked Questions
Quick answers to the most common questions about buying ASND stock.
What is ASND's P/E ratio?
Ascendis Pharma A/S (ASND) trailing twelve-month P/E ratio is 19.0x, based on TTM diluted EPS of $12.96. The 5-year average P/E is 23.5x and the historical range spans 16.9x to 30.3x.
Is ASND stock overvalued or undervalued?
ASND trades at 19.0x P/E, near its 5-year average of 23.5x. The 33th percentile ranking within the 16.9x–30.3x historical range places valuation within normal bounds.
Is ASND stock expensive?
ASND is fairly valued relative to its own history. The current P/E of 19.0x is near the 5-year average of 23.5x (33th percentile of historical range).
What is ASND's historical P/E range?
Over the past 5 years, ASND's P/E ratio has ranged from 16.9x to 30.3x, with a median of 23.3x and an average of 23.5x. The current P/E of 19.0x places the stock at the 33th percentile of this range. Full historical data spans 2026–2026.
How does ASND's P/E compare to the S&P 500?
ASND trades at 19.0x P/E versus the S&P 500 median of 21.5x. The 12% discount to the market suggests lower growth expectations or perceived higher risk.
How does ASND's valuation compare to Healthcare peers?
Ascendis Pharma A/S P/E of 19.0x compares to the Healthcare sector median of 25.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ASND's PEG ratio?
ASND PEG ratio is N/A, based on a P/E of 19.0x and EPS growth of 44.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ASND's earnings yield?
ASND earnings yield is 5.26%, the inverse of its 19.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.